Patient data can, if properly used, the cost of health care lower, by making the System more efficient and at the same time, the quality of life of the patients improve and ultimately save lives. Drug data in combination with patient data can go a step further, in order to improve patient satisfaction, increase drug safety and user-friendliness.
The improvement in the quality of the data and analysis may be in areas such as predictive medicine, the Management of patient relations, the Management of health care and the measurement of the effectiveness of certain treatments are effective.
It is estimated that only 50% of patients comply with globally prescribed medications and their instructions, which is more than 50% of doctor’s visits, about 40% of the long-time stays and about 40% of hospital admissions caused.
Overall, the global cost of non-compliance will amount to more than 700 billion USD per year with an annual increase of 13%. Therefore, it is crucial to bring more patients to your medication as prescribed to take, in order to improve the health care and the quality of the results. In this way, national healthcare providers can use their resources in an efficient and high quality results, based on best practice deliver.
Recent news and changes in the law have brought the use of personal data in the implementation of the General data protection regulation in Europe, in the foreground. It provides that all EU citizens know, what personal data is stored by you, and give you the control over how they are used.
A way around this “data puzzles” is to decrypt to the use of standardized and anonymized data sets. Curaizon, a pioneer in the medical Adherence technologies has developed CuraData, a solution of anonymized patients ‘ personal data, so that they can be used by health service providers, medical researchers and pharmaceutical companies.
Using machine Learning and AI technologies will create the CuraData-platform datasets, which are based on anonymised Big Data generated, and to promote end-to-end data integration, collaboration between different actors in the health care and predictive modeling of the efficiency of different drugs.
The adherence technology will also help to improve the understanding of the efficacy of medicinal products, to reduce the cost of research and development in medicine, and at the same time the competition in the pharmaceutical sector. Curaizons data are stored in a Cloud, with permissions, and pointers that control the data in the Blockchain and the security, transparency and immutability of medical records to ensure, as access to it is restricted by the corresponding rules.
The CuraData platform is provided through national health services. The more input data for patients and health services are available, the better the quality and functionality of the generated records.
For example, Doctors and practitioners through feedback from patients will exist a valuable insight into the shortcomings of existing treatments, and real-time information about non-compliance will help you to understand complications that may be associated with a specific drug or a specific form of treatment.
This Feedback can be incorporated in the System, in order to develop a Best Practice. In return, scientists and researchers pharmaceutical companies can use this data within the CuraData platform to generate unique insights and the Ecosystem to develop.
The indirect co-operation and information exchange of all parties will help to reduce cost and waste in the health care and medical research. Used properly, advanced Adherence Data Analytics can improve the quality and efficiency in national health systems for the benefit of patients and providers.
Curaizon offers potential investors the chance to be Initial Coin Offering (ICO) in its technologies to shop. The tokens that are referred to as CTKN, provide access to the unique CuraData platform. There is no other option, this records access, everything is published in real time on the Blockchain. The public Token sale started at 8. June 2018.